In vitro mechanistic experiments (42) further confirmed the causal role of SLFN11: in bladder cancer cell lines, SLFN11 gene knockout led to resistance to cisplatin, while epigenetic modification drugs (such as 5-azacytidine and entinostat) restored SLFN11 expression and resensitized SLFN11-negative cells to cisplatin and carboplatin. Here, SLFN11 is linked to urinary bladder carcinoma.